Israel’s pharmacy retail market has long operated with a focus on service and brand partnerships, a model dominant chains have used to maintain customer loyalty. Pharm Plus is introducing a different approach, emphasizing affordability over traditional retail experiences. The first location, a 150-square-meter store near Tel Aviv University, opened this month with a price list that mirrors grocery promotions: 9.9 shekels for Always pads, 12.9 shekels for Colgate Total toothpaste, and 22.9 shekels for Pampers Premium diapers. Even higher-end products, such as Tom Ford Black Orchid perfume, are priced at 394.9 shekels for 100 milliliters, significantly below typical retail costs.
Why a Grocery Giant Is Betting on Pharmacy
Sappir Group’s entry into pharmacy retail builds on its existing strength in Israel’s grocery sector. The company, controlled by brothers Oren and Avinom Sappir, operates Neto Savings, Super Sappir, and *Hamachlat Shelanu*, giving it significant influence over suppliers and real estate. The launch of Pharm Plus, supported by a substantial investment, marks the beginning of a broader push into non-food retail, timed to enhance its market position ahead of a planned IPO.
According to reports, the company views this expansion as a logical step in its growth strategy. The group aims to diversify its retail footprint beyond food, aligning with its plans for a stock market listing. While pharmacy retail is a new sector for Sappir, the move reflects a strategic effort to enter a market where pricing and accessibility have traditionally taken a backseat to service and brand loyalty. Pharm Plus’s approach disrupts this model by introducing deep discounts on widely used products.
Household spending on pharmacy and personal care products has seen a steady increase in recent years, reflecting growing demand. The sector remains fragmented, with no single chain holding a dominant share. For Sappir, this presents an opportunity to leverage its supply chain efficiency and consumer trust built through its grocery brands. Whether this trust translates to pharmacy retail remains to be seen, but the company’s existing infrastructure provides a strong foundation for expansion.
The Discount Dilemma: Volume vs. Margins
Pharm Plus’s pricing strategy stands in stark contrast to how established pharmacy chains operate. Super-Pharm, Israel’s largest pharmacy retailer, has focused on private-label products, loyalty programs, and a premium in-store experience, positioning its locations as destinations rather than mere retail outlets. Pharm Plus, however, adopts a no-frills approach, resembling a discount warehouse. The first store’s location, described as less central, suggests an emphasis on cost efficiency over prime foot traffic. Shelves are stocked with well-known brands at prices far below competitors: Gillette Fusion razors for 119.9 shekels (compared to ~150 shekels elsewhere) and Sano Maxima fabric softener for 7.9 shekels, roughly a third of typical retail costs.
The challenge for Sappir lies in the fundamental differences between grocery and pharmacy retail. In food retail, discounts on staples like milk or bread can attract customers to higher-margin categories such as produce or prepared foods. Pharmacy retail lacks these natural upsell opportunities. A shopper drawn in by low-priced pads may not explore other product categories. To compensate for thinner margins, Pharm Plus will need to rely on high sales volume, which depends on convincing price-sensitive consumers to switch from established chains.
Some analysts suggest the real test will be whether Pharm Plus can balance affordability with consumer expectations. Pharmacy retail is often associated with expertise and service, not just low prices. If the chain struggles to meet these expectations, discounts alone may not be enough to build lasting customer loyalty. While Sappir’s grocery operations provide advantages in supply chain management, pharmacy retail demands specialized skills, including inventory management for a vast array of products, relationships with pharmaceutical distributors, and adherence to Israel’s strict regulations on over-the-counter sales.
Competitors Aren’t Waiting to React
Established pharmacy chains like Super-Pharm have yet to respond directly to Pharm Plus’s launch, but their silence may not last. In the grocery sector, Sappir’s Neto Savings has already influenced competitors like Rami Levy and Shufersal to adopt more aggressive pricing, often leading to industry-wide margin pressures. A similar dynamic could unfold in pharmacy retail, where Super-Pharm’s gross margins are significantly higher than those in grocery.
The key question is whether competitors will match Pharm Plus’s discounts or focus on enhancing their premium offerings. Super-Pharm’s recent expansion into private-label beauty products indicates a preference for differentiation over price competition. However, if Pharm Plus gains traction, even premium players may be forced to adjust their strategies. As one former retail executive noted, the moment a chain begins losing market share to a discounter, the pressure to respond becomes difficult to ignore. The challenge lies in whether competitors can afford to engage in a price war without eroding their own profitability.
Regulatory factors could also shape the competitive landscape. Israel’s Ministry of Health has historically allowed pharmacy pricing to remain largely unregulated, but past interventions suggest this could change if the market becomes destabilized. In a previous case, the ministry capped prices on certain over-the-counter medications following complaints from independent pharmacies. If deep discounting disrupts the sector, similar oversight could emerge, potentially altering the playing field for all players.
What to Watch in the Next 12 Months
Pharm Plus’s trajectory will depend on several critical factors: the pace of its store expansion, the timing of Sappir’s IPO, and early sales performance. While the company has not disclosed specific plans for new locations, industry reports suggest a gradual rollout, primarily in the Tel Aviv and central regions. Securing favorable leases in high-traffic areas will be essential, as the first store’s less central location may have been a cost-saving measure rather than a long-term strategy.
The planned 2027 IPO adds urgency to the expansion. Investors will closely monitor whether Pharm Plus can scale without sacrificing margins, a challenge even experienced discounters have faced. If the chain demonstrates consistent foot traffic and sales growth, it could strengthen Sappir’s valuation. Conversely, if early results fall short, the IPO timeline may be adjusted, or the pharmacy initiative could be scaled back.
For consumers, the initial signs are encouraging. A comparison of Pharm Plus’s launch prices against competitors shows savings of 20-40% on essentials, particularly on high-turnover items like diapers and hygiene products. Whether these savings persist—or spread to other chains—will depend on Pharm Plus’s ability to build scale quickly. In the meantime, shoppers may gain a new option: a pharmacy that prioritizes affordability over traditional service, potentially reshaping expectations in Israel’s retail landscape.
Ultimately, this shift could redefine the sector—or reveal the limits of disruption in an industry built on trust and expertise.
